The Technical Analyst
Neuropathix, Inc. [NPTX]
Exchange: OTC Sector: Healthcare Industry: Biotechnology
Neuropathix, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0003
America/New_York / 13 jun 2023 @ 12:01
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.0281 mill |
| EPS: | -0.0400 |
| P/E: | -0.0075 |
| Earnings Date: | N/A |
| SharesOutstanding: | 93.81 mill |
| Avg Daily Volume: | 0.0136 mill |
| RATING 2023-06-13 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0075 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0075 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0003 - 0.0003 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-06 | Petkanas Dean | Sell | 10 000 | Common Stock |
| 2022-06-07 | Petkanas Dean | Sell | 50 000 | Common Stock |
| 2022-06-08 | Petkanas Dean | Sell | 21 836 | Common Stock |
| 2022-06-09 | Petkanas Dean | Sell | 238 164 | Common Stock |
| 2022-06-13 | Petkanas Dean | Sell | 300 000 | Common Stock |
| INSIDER POWER |
|---|
| -100.00 |
| Last 56 transactions |
| Buy: 20 518 991 | Sell: 5 700 000 |
Forecast:
01:40 - $0
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0003 (0.00% ) |
| Volume | 0.0100 mill |
| Avg. Vol. | 0.0136 mill |
| % of Avg. Vol | 73.55 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NPTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NPTX
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.
Latest Press Releases
2021-09-28 09:00:00 - Press Release
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant From National Institute Of Neurological Disorders And Stroke (ninds)
Pharmaceutical assets include company's non-opioid anti-inflammatory compound kls-13019 to treat chemotherapy induced peripheral neuropathy (cipn) company's strategy is to utilize the phase 2 study grant funds to complete preclinical studies in cipn and ready the company to begin fda phase 1 human clinical trials doylestown, pa / accesswire / september 28, 2021 / neuropathix, inc. ("neuropathix" or the "company") (otcqb:nptx), a socially responsible pain management life sciences company, today announces that its wholly owned subsidiary, kannalife sciences, inc. has received a notice of award from the national institute of neurological disorders and stroke (ninds) of the national institutes of health (nih) for a $2...
2021-08-24 09:00:00 - Press Release
Neuropathix, Inc. Forms Dermique Incorporated Its New Wholly Owned Subsidiary For The Ownership And Commercialization Of The Company's Over-the-counter Cosmeceutical Assets
Cosmeceutical assets include company's lead anti-inflammatory otc cosmeceutical compound called lea™ (limonenyldihydroxybenzyl ethoxycarbonyl azetidine) company's strategy is to enable dermique to focus on commercializing near term revenue drivers like lea™, other cosmeceuticals doylestown, pa / accesswire / august 24, 2021 / neuropathix, inc. ("neuropathix" or the "company") (otcqb:nptx), a socially responsible pain management life sciences company, today announces the formation of dermique incorporated ("dermique"), a new wholly owned subsidiary to hold, manage, commercialize and market the intellectual property assets related to the company's cosmeceutical ingredients ("otc ip"). the company's strategy in setting up dermique is to set apart its product platforms and near-term revenue drivers for over-the-counter (otc) use from its longer range pharmaceutical and drug discovery pipeline.
2021-07-20 09:00:00 - Press Release
Neuropathix, Inc. Announces Publication Of Pct Patent Application For The Treatment Of Radiation Dermatitis And Other Skin Disorders
Doylestown, pa / accesswire / july 20, 2021 / neuropathix, inc. ("neuropathix" or the "company") (otcqb:nptx), a socially responsible pain management life sciences company, announced today the publication of the global patent cooperation treaty (pct) patent under publication no. wo/2021/097351 "functionalized 1,3-benzene diols and their method of use for the treatment of radiation dermatitis and other skin disorders.
2021-01-25 09:00:00 - Press Release
Neuropathix, Inc. Ceo Recaps 2020 Advances And Potential Ahead
Doylestown, pa., jan. 25, 2021 (globe newswire) -- neuropathix, inc. (“neuropathix” or the “company”) (otcqb: nptx), a socially responsible pain management life sciences company, announced today that it has issued a letter to its shareholders providing commentary on the company's recent initiatives and corporate updates.
Latest News
2021-09-28 09:00:00 - Accesswire
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
Pharmaceutical Assets Include Company's Non-Opioid Anti-inflammatory Compound KLS-13019 to Treat Chemotherapy Induced Peripheral Neuropathy (CIPN) Company's Strategy is to Utilize the Phase 2 Study Grant Funds to Complete Preclinical Studies in CIPN and Ready the Company to Begin FDA Phase 1 Human Clinical Trials DOYLESTOWN, PA / ACCESSWIRE / September 28, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that its wholly owned subsidiary, Kannalife Sciences, Inc. has received a notice of award from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) for a $2...
2021-08-24 09:00:00 - Accesswire
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets
Cosmeceutical Assets Include Company's Lead Anti-inflammatory OTC Cosmeceutical Compound called LEA™ (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine) Company's Strategy is to Enable Dermique to Focus on Commercializing Near Term Revenue Drivers like LEA™, Other Cosmeceuticals DOYLESTOWN, PA / ACCESSWIRE / August 24, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces the formation of Dermique Incorporated ("Dermique"), a new wholly owned subsidiary to hold, manage, commercialize and market the intellectual property assets related to the company's cosmeceutical ingredients ("OTC IP"). The Company's strategy in setting up Dermique is to set apart its product platforms and near-term revenue drivers for over-the-counter (OTC) use from its longer range pharmaceutical and drug discovery pipeline.
2021-07-20 09:00:00 - Accesswire
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
DOYLESTOWN, PA / ACCESSWIRE / July 20, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publication of the global Patent Cooperation Treaty (PCT) Patent under Publication No. WO/2021/097351 "Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders.
2021-01-25 09:00:00 - GlobeNewsWire
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today that it has issued a letter to its shareholders providing commentary on the Company's recent initiatives and corporate updates.